Increased risk of myelotoxicity in elderly patients with non-hodgkin lymphoma - The case for routine prophylaxis with colony-stimulating factor beginning in the first cycle of chemotherapy

被引：37

作者：

Balducci, L

Repetto, L

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Senior Adult Oncol Program, Tampa, FL 33612 USA

[2] Ist Nazl Riposa & Cura Anziani, Unita Operat Geriatria Oncol, Rome, Italy

来源：

CANCER | 2004年 / 100卷 / 01期

关键词：

myelotoxicity; neutropenia; elderly; chemotherapy; colony-stimulating factor (CSF); non-Hodgkin lymphoma (NHL);

D O I：

10.1002/cncr.11861

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neutropenia is the major dose-limiting toxicity of myelosuppressive chemotherapy in patients with cancer. Because of the high incidence of neutropenic complications and death in the early cycles of chemotherapy and the potential for improved outcomes, prophylaxis with colony-stimulating factor beginning in the first cycle should be routinely considered in elderly patients with non-Hodgkin lymphoma who are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy regimens.

引用

收藏

页码：6 / 11

页数：6

相关论文

共 38 条

[21] THE NATURE OF ADVERSE EVENTS IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-II [J].

LEAPE, LL ;

BRENNAN, TA ;

LAIRD, N ;

LAWTHERS, AG ;

LOCALIO, AR ;

BARNES, BA ;

HEBERT, L ;

NEWHOUSE, JP ;

WEILER, PC ;

HIATT, H .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (06) :377-384

[22] PROGNOSTIC-SIGNIFICANCE OF RECEIVED RELATIVE DOSE INTENSITY IN NON-HODGKINS-LYMPHOMA PATIENTS - APPLICATION TO LNH-87 PROTOCOL [J].

LEPAGE, E ;

GISSELBRECHT, C ;

HAIOUN, C ;

SEBBAN, C ;

TILLY, H ;

BOSLY, A ;

MOREL, P ;

HERBRECHT, R ;

REYES, F ;

COIFFIER, B .

ANNALS OF ONCOLOGY, 1993, 4 (08) :651-656

[23] The economics of febrile neutropenia: Implications for the use of colony-stimulating factors [J].

Lyman, GH ;

Kuderer, N ;

Greene, J ;

Balducci, L .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) :1857-1864

[24]

LYMAN GH, 2002, P AN M AM SOC CLIN, V21, pA358

[25] RANDOMIZED PHASE-II COMPARISON OF STANDARD CHOP WITH WEEKLY CHOP IN ELDERLY PATIENTS WITH NON-HODGKINS-LYMPHOMA [J].

MEYER, RM ;

BROWMAN, GP ;

SAMOSH, ML ;

BENGER, AM ;

BRYANTLUKOSIUS, D ;

WILSON, WEC ;

FRANK, GL ;

LEBER, BF ;

STERNBACH, MS ;

FOSTER, GA ;

SKINGLEY, P ;

LEVINE, MN .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) :2386-2393

[26]

Moore TD, 2002, BLOOD, V100, p571A

[27] The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis [J].

Morrison, VA ;

Picozzi, V ;

Scott, S ;

Pohlman, B ;

Dickman, E ;

Lee, M ;

Lawless, G ;

Kerr, R ;

Caggiano, V ;

Delgado, D ;

Fridman, M ;

Ford, J ;

Carter, WB .

CLINICAL LYMPHOMA, 2001, 2 (01) :47-56

[28] IN SEARCH OF AN OPTIMAL REGIMEN FOR ELDERLY PATIENTS WITH ADVANCED-STAGE DIFFUSE LARGE-CELL LYMPHOMA - RESULTS OF A PHASE-II STUDY OF P-DOCE CHEMOTHERAPY [J].

OREILLY, SE ;

CONNORS, JM ;

HOWDLE, S ;

HOSKINS, P ;

KLASA, R ;

KLIMO, P ;

STUART, DS .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2250-2257

[29] 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines [J].

Ozer, H ;

Armitage, JO ;

Bennett, CL ;

Crawford, J ;

Demetri, GD ;

Pizzo, PA ;

Schiffer, CA ;

Smith, TJ ;

Somlo, G ;

Wade, JC ;

Wade, JL ;

Winn, RJ ;

Wozniak, AJ ;

Somerfield, MR .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3558-3585

[30] Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting [J].

Repetto, L ;

Carreca, I ;

Maraninchi, D ;

Aapro, M ;

Calabresi, P ;

Balducci, L .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (02) :123-128

← 1 2 3 4 →